Robotic-guided spinal surgeries reduce both complications and the number of revision surgeries needed, according to a new report released today by Mazor Robotics (NSDQ:MZOR).
The study shows that spinal surgeries performed using the company’s guidance system had a five-fold reduction in surgical complications. Such technology also contributed to a seven-fold reduction in revision surgeries versus freehand-based minimally invasive lumbar fusion surgeries, a Mazor news release indicates.
The study, which started in 2014, was designed to assess the clinical impact of robotic-guidance, compared to fluoro-guidance. The company indicated that 379 patients enrolled in the study, of which 287 were in the robotic-guided arm and 92 in the fluoro-guided control arm.
The results were collected from 10 surgeons in nine U.S. sites and disclosed at the North American Spine Society’s annual meeting in Florida.
Israel-based Mazor Robotics, founded in 2001, is a medical device company and manufacturer of a robotic guidance system. In 2016, it posted revenue of $36.3 million compared with $26.1 million in 2015.
In early October, Mazor Robotics shares ticked up after the company reported its preliminary third-quarter sales numbers and disclosed plans to post sales of $17.2 million for the three months ending Sept. 30.
In September, the company closed a third, $40 million tranche as part of a deal with Medtronic (NYSE:MDT).
Studies show that spine surgeries have five times the amount of surgery problems using the company’s guidance method. Such technology has contributed to seven times the reduction of recovery operations and freehand-based low penetrating hip intelligence surgeries